A Cleveland Clinic study of pediatric patients with epilepsy and no mental health history found unprecedentedly high rates of depression, anxiety and suicidal thoughts.
Already exhausted healthcare professionals are at heightened risk of psychological distress this winter. This article addresses the trends and offers tips for safeguarding mental health.
A psychiatrist who worked with the group that discovered ketamine’s antidepressant effects traces the path to the randomized trial he’s now leading to compare ketamine with electronconvulsive therapy.
E-cigarette or Vaping product use-Associated Lung Injury (EVALI) is a relatively recent epidemic, clinical presentation remains quite variable, and there is no consensus among pediatric pulmonologists as to the best treatment approach. In this article, Fariba Rezaee, MD, presents a case of EVALI in a 15-year-old female who presents with deteriorating respiratory status.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Even as functional performance diminished, depressed patients with multiple sclerosis were not able to recognize the decline.
New practices prompted by the pandemic promise to enhance mental health care offerings to patients and healthcare providers in ways that will endure after the crisis ends.
Obstructive sleep apnea is linked not just with heart disease, but with poor quality of life, drowsy driving, depression, metabolic disease and cognitive impairment.
Cardiac arrhythmias are a breeding ground for depression and anxiety, a recent study finds. Electrophysiologist Peter Aziz, MD, provides clinical context to the research, which found that adolescents with cardiac arrhythmias were 9x more likely to develop or be on medication for depression and anxiety.
Sleep interventions may help improve quality of life of patients with both endometrial cancer and obesity, a new Case Comprehensive Cancer Center study finds. Co-authors Jay Alberts, PhD, and Chad Michener, MD, explain.
The newly approved intranasal ketamine derivative helps fill clear gaps in short-term therapy, says one expert, but questions remain around its long-term effects and affordability.